Editor's Note
The Food & Drug Administration on June 4 announced that it had approved new labeling on potential risks for liquid-filled intragastric balloons by Apollo Endosurgery and ReShape Lifesciences.
The new labeling for the Orbera and ReShape balloon systems includes more information about possible deaths linked to the use of these devices.
The promise of quicker recovery and fewer complications from sedation,…
New York, New York (January 31, 2024)–Sonio today announced that…
The US Food and Drug Administration receives more than 100,000…